Cooley Closes 2nd Life Sciences Deal In 2 Days

Law360, New York (October 18, 2012, 4:50 PM EDT) -- Cooley LLP has closed its second sell-side pharmaceutical deal of the week, representing Presidio Pharmaceuticals Inc. in its $101 million acquisition by BioCryst Pharmaceutical Inc., announced Thursday.

That follows Tuesday's announcement that the California-based firm, whose mergers and acquisitions practice has a strong bent toward life sciences and technology, advised Surpass Medical Ltd. in its acquisition by Stryker Corp. for $135 million.

In Thursday's deal, BioCryst will issue 24.5 million shares, valued at $4.11 apiece at Wednesday's close, for privately held Presidio to team up on...
To view the full article, register now.